biostudies-literatureUnknown8(10)Kloverpris HN<h4>Background</h4>HIV Gag-specific CD4+ and CD8+ T-cell responses are important for HIV immune control. Pulsing overlapping Gag peptides on autologous lymphocytes (OPAL) has proven immunogenic and effective in reducing viral loads in multiple pigtail macaque studies, warranting clinical evaluation.<h4>Methodology</h4>We performed a phase I, single centre, placebo-controlled, double-blinded and dose-escalating study to evaluate the safety and preliminary immunogenicity of a novel therapeutic vaccine approach 'OPAL-HIV-Gag(c)'. This vaccine is comprised of 120 15mer peptides, overlapping by 11 amino acids, spanning the HIV Gag C clade sequence proteome, pulsed on white blood cells enriched from whole blood using a closed system, followed by intravenous reinfusion. Patients with undetectablePloS onee74389https://www.ebi.ac.uk/biostudies/studies/S-EPMC3790804biostudies-literatureNon-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.PMC3790804Hayes PWalker BDRiddell LSullivan MChen FBoffito MGoulder PAtkins MJackson AHandley AKloverpris HNGilmour JAckland JfalseNon-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.<h4>Background</h4>HIV Gag-specific CD4+ and CD8+ T-cell responses are important for HIV immune control. Pulsing overlapping Gag peptides on autologous lymphocytes (OPAL) has proven immunogenic and effective in reducing viral loads in multiple pigtail macaque studies, warranting clinical evaluation.<h4>Methodology</h4>We performed a phase I, single centre, placebo-controlled, double-blinded and dose-escalating study to evaluate the safety and preliminary immunogenicity of a novel therapeutic vaccine approach 'OPAL-HIV-Gag(c)'. This vaccine is comprised of 120 15mer peptides, overlapping by 11 amino acids, spanning the HIV Gag C clade sequence proteome, pulsed on white blood cells enriched from whole blood using a closed system, followed by intravenous reinfusion. Patients with undetectable2013-01-01T00:00:00Z20132026-05-01T15:19:26.624Z2026-04-20T03:09:57.596ZS-EPMC37908042412445110.1371/journal.pone.0074389